13 recruiting, 10 not yet recruiting, 9 unknown, 8 active not recruiting. 17 Phase 2, 15 Phase 3, 8 Phase 4, 5 Not applicable, 4 Phase 1.
Follow telitacicept: new trials by email Literature Review of telitacicept trials Research Report on telitacicept
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease Part A - Placebo for IBI355, Part B -Telitacicept, PartB -Placebo for Telitacicept - Sjögren's Disease | Phase 2 | Not yet recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 198 | 2026-10-15 | 2026-09-23 |
| IBI3034 Study in Healthy Adults and Patients With Primary IgA Nephropathy IBI3034, Placebo, Telitacicept - IgA Nephropathy (IgAN) | Phase 1 | Not yet recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 100 | 2026-10-15 | 2026-10-21 |
| Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis Telitacicept 160mg, Standard therapy - Difficult-to-treat Rheumatoid Arthritis, Rheumatoid Arthritis | Phase 2 | Recruiting | Peking University People's Hospital | 420 | 2026-09-01 | 2026-09-01 |
| Sequential Daratumumab Followed by Telitacicept for the Treatment of ABMR After Kidney Transplantation-A Phase IIa Clinical Trial Methylprednisolone (MP), Daratumumab, Telitacicept - Antibody-mediated Rejection, Antibody-Mediated Rejection (AMR) | Phase 2 | Active not recruiting | First Affiliated Hospital, Sun Yat-Sen University | 20 | 2026-06-20 | 2026-10-29 |
| Chinese Adults With Kidney Disease ADX-038, Telitacicept - Immunoglobulin A Nephropathy (IgAN), Complement 3 Glomerulopathy (C3G) | Phase 2 | Recruiting | ADARx Pharmaceuticals, Inc. | 30 | 2026-05-21 | 2026-09-03 |
| Clinical Efficacy of Telitacicept in Sjögren's Disease With Interstitial Lung Disease Telitacicept 160mg, Conventional treatment - Sjögren's Disease, Interstitial Lung Disease | Recruiting | Peking University People's Hospital | 60 | 2026-05-01 | 2026-09-28 | |
| Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung Disease Telitacicept, Placebo - CTD-ILD | Phase 3 | Not yet recruiting | RemeGen Co., Ltd. | 260 | 2026-04-20 | 2026-04-09 |
| A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia Gravis Telitacicept - Effectiveness | Not applicable | Not yet recruiting | The Children's Hospital of Zhejiang University School of Medicine | 30 | 2026-03-10 | 2026-03-06 |
| Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease Telitacicept, Placebo - Primary Sjogren's Disease | Phase 3 | Recruiting | Vor Biopharma | 250 | 2026-02-26 | 2026-10-19 |
| TELITACICEPT IN INFLAMMATORY MYOPATHIES(TELITACICEPT-IM) Telitacicept 240mg - Inflammatory Myopathy | Phase 2 / Phase 3 | Not yet recruiting | Zhongming Qiu | 30 | 2026-02-02 | 2026-01-21 |
| A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) Telitacicept, Placebo - Myasthenia Gravis, Ocular | Phase 3 | Recruiting | RemeGen Co., Ltd. | 120 | 2026-01-13 | 2026-04-09 |
| The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment Glucocorticoids, belimumab, Telitacicept - Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 2 | Recruiting | Nanjing University School of Medicine | 50 | 2025-12-08 | 2026-03-12 |
| Telitacicept for Refractory Chronic Inflammatory Demyelinating Polyneuropathy Conventional Therapy, Telitacicept - Refractory Chronic Inflammatory Demyelinating Polyneuropathy | Not applicable | Active not recruiting | Sichuan Academy of Medical Sciences | 76 | 2025-09-26 | 2026-05-19 |
| Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculitis Nephritis Telitacicept - IgA Nephropathy (IgAN), IgAVN | Phase 3 | Not yet recruiting | Guixia Ding | 124 | 2025-08-01 | 2025-07-10 |
| Telitacicept for PGNMID: A Single-Arm Study Telitacicept 160mg - Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits | Phase 2 | Active not recruiting | Peking University First Hospital | 10 | 2025-07-12 | 2025-08-08 |
| Telitacicept for the Treatment of Refractory RA Telitacicept - Rheumatoid Arthritis (RA) | Phase 4 | Not yet recruiting | Chinese SLE Treatment And Research Group | 30 | 2025-06-10 | 2025-06-06 |
| Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis Efgartigimod + Telitacicept (1-week interval) group, Efgartigimod + Telitacicept (2-week interval) group, Telitacicept-only group - Myasthenia Gravis, Autoimmune Diseases | Not applicable | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 60 | 2025-02-01 | 2025-02-14 |
| Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis Telitacicept, Mycophenolate Mofetil - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 38 | 2025-01-06 | 2025-02-11 |
| Efficacy and Safety of Telitacicept in IgAN Telitacicept 240mg, Glucocorticoid - IgA Nephropathy (IgAN), Kidney Diseases | Not applicable | Recruiting | Ruijin Hospital | 118 | 2024-12-06 | 2025-01-01 |
| Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis Telitacicept - Myasthenia Gravis, Autoimmune Diseases | Phase 4 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 30 | 2024-12-01 | 2024-12-09 |
Showing 20 of 49. Sign in to see all of them.
Lupus Erythematosus, Systemic (11) · Glomerulonephritis, IGA (8) · Myasthenia Gravis (6) · Autoimmune Diseases (5) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (3) · Lupus Nephritis (3) · Sjogren's Syndrome (3) · Antiphospholipid Syndrome (2) · Arthritis, Rheumatoid (2) · Connective Tissue Diseases (2) · Thrombocytopenia (2) · Glomerulonephritis, Membranoproliferative (1) · Immune System Diseases (1) · Kidney Diseases (1) · Lung Diseases, Interstitial (1)
RemeGen Co., Ltd. (10) · Vor Biopharma (4) · Chinese SLE Treatment And Research Group (3) · Second Affiliated Hospital, Zhejiang University, School of Medicine (3) · First Affiliated Hospital of Wenzhou Medical University (2) · Innovent Biologics (Suzhou) Co. Ltd. (2) · Peking Union Medical College Hospital (2) · Peking University People's Hospital (2) · Renmin Hospital of Wuhan University (2) · The Children's Hospital of Zhejiang University School of Medicine (2) · ADARx Pharmaceuticals, Inc. (1) · Beijing Hospital (1) · Fen Li (1) · First Affiliated Hospital, Sun Yat-Sen University (1) · Guanmin Gao (1)
China (39) · United States (5) · Argentina (2) · Australia (2) · Bulgaria (2) · Georgia (2) · Poland (2) · Spain (2) · Belgium (1) · Brazil (1) · Canada (1) · Chile (1) · Colombia (1) · Czechia (1) · France (1)
Anbin Huang, MD. (1) · Arezoo Mirad (1) · Dongbao Zhao, MD. (1) · Fen Li, MD. (1) · Fen Li, doctor (1) · Fude Zhou, MD (1) · Gao Guanmin (1) · Guanmin Gao, MD. (1) · Hongbin Li, MD. (1) · Hongmei Song, M.D. (1) · Hongsheng Sun, MD. (1) · Hui Luo, MD. (1) · JIng Li, M.D. (1) · Jianhua Mao, MD (1)
PMID 38299639, PMID 16947627, PMID 39383505, PMID 40465397, PMID 41200184, PMID 42127391, PMID 42170450